![]() | |
Clinical data | |
---|---|
Trade names | Rezlidhia |
Other names | FT-2102 |
License data |
|
Routes of administration | By mouth |
ATC code | |
Legal status | |
Legal status | |
Identifiers | |
CAS Number | |
PubChem CID | |
IUPHAR/BPS | |
DrugBank | |
ChemSpider | |
UNII | |
KEGG | |
ChEMBL | |
PDB ligand | |
Chemical and physical data | |
Formula | C18H15ClN4O2 |
Molar mass | 354.79 g·mol−1 |
3D model (JSmol) | |
| |
|
Olutasidenib, sold under the brand name Rezlidhia, is an anticancer medication used to treat relapsed or refractory acute myeloid leukemia with a susceptible IDH1 mutation. [2] [3] Olutasidenib is an isocitrate dehydrogenase-1 (IDH1) inhibitor. [2] It is taken by mouth. [2]
The most common adverse reactions include nausea, fatigue/malaise, arthralgia, constipation, leukocytosis, dyspnea, fever, rash, mucositis, diarrhea, and transaminitis. [4]
Olutasidenib was approved for medical use in the United States in December 2022, [2] [3] [4] [5] [6] [7] based on the phase 1 results of a phase 1/2 trial. [8]
Olutasidenib is indicated for the treatment of adults with relapsed or refractory acute myeloid leukemia with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation as detected by an FDA-approved test. [2] [3] [4]
Olutasidenib is the international nonproprietary name. [9]